Post by account_disabled on Dec 31, 2023 5:14:26 GMT 1
Athe BCA states that there must be precise indications to reach the conclusion that an acquisition could lead to an abuse of a dominant position. Upon closer inspection the BCA found no such indications at first sight. While acknowledging ABIs dominant position in the ontrade and offtrade Belgian beer markets the acquisition was seen to result in only a limited increase in market share and also limited growth in the beer connoisseur segment. The BCA examined more closely the arguments put forward by the AM according to which the acquisition causes an abuse of a dominant position would make ABI the only brewer with a complete portfolio of major brands would.
Prevent competitors from strengthening their position in the beer connoisseur Country Email List segment it would deprive competitors of the weapon of infiltration in the market would create an increased dependence of small brewers on the expert segment owned by ABI. Based on an analysis of various factors the BCA rejected each argument raised by the AM. In the end the BCA concluded that there was insufficient evidence of a prima facie violation of the law or of serious and irreparable harm. At the same time the BCA warned that if the ABI were to prevent the sale of business experts such conduct would at a later stage breach Articles and of the.
Fundamental Treaty of the European Union would also have taken into account the binding commitments assumed by ABI before the European Commission. Sursa Lexology Leave a reply Your email address will not be published. Mandatory fields are marked with Comment Name Email Site web Save my name email and website in this browser for the next time I comment. iclesemail and website in this browser for the next time I comment. Exorbitant drug pricing m fine Competition law minutes Adelina Voicu January The UKs Competition and Markets Authority has fined pharmaceutical companies Pfizer and.
Prevent competitors from strengthening their position in the beer connoisseur Country Email List segment it would deprive competitors of the weapon of infiltration in the market would create an increased dependence of small brewers on the expert segment owned by ABI. Based on an analysis of various factors the BCA rejected each argument raised by the AM. In the end the BCA concluded that there was insufficient evidence of a prima facie violation of the law or of serious and irreparable harm. At the same time the BCA warned that if the ABI were to prevent the sale of business experts such conduct would at a later stage breach Articles and of the.
Fundamental Treaty of the European Union would also have taken into account the binding commitments assumed by ABI before the European Commission. Sursa Lexology Leave a reply Your email address will not be published. Mandatory fields are marked with Comment Name Email Site web Save my name email and website in this browser for the next time I comment. iclesemail and website in this browser for the next time I comment. Exorbitant drug pricing m fine Competition law minutes Adelina Voicu January The UKs Competition and Markets Authority has fined pharmaceutical companies Pfizer and.